Joint Programmes That Actually Finish the Course

Soundness decides careers in both horses and camels, and joint therapy is where a lot of yard money goes. A meaningful fraction of it is wasted, not because the products do not work but because the courses are not finished.

The products and their protocols

Polysulphated glycosaminoglycan (PSGAG) is given intramuscularly as a course of seven injections at four-day intervals — roughly four weeks. It inhibits the catabolic enzymes that degrade cartilage matrix and supports synovial fluid quality. It has one of the better controlled-trial evidence bases in this category.

The failure mode: three or four injections, no obvious change, course abandoned. The protocol is seven for a reason.

Hyaluronic acid is given intra-articularly for a specific joint, or intravenously as a systemic protocol — commonly 40 mg weekly for three weeks. Intra-articular administration is a veterinary procedure requiring surgical asepsis, because septic arthritis following a contaminated joint injection ends careers.

The failure mode: repeated intra-articular injection of a joint that needs imaging and a diagnosis rather than another injection.

Pentosan polysulphate is given intramuscularly, typically once weekly for four weeks. It has chondroprotective and fibrinolytic activity and improves subchondral bone perfusion.

Oral chondroprotectives — glucosamine, chondroitin, MSM — work slowly and modestly. Six to eight weeks before judging, and their role is maintenance between injectable courses rather than treatment of an acute problem.

Why courses get abandoned

Expecting an injectable response. These are not analgesics. A horse given a corticosteroid intra-articularly is often visibly better in 48 hours. A horse on day four of a PSGAG course is not, because the mechanism is structural rather than analgesic.

No objective baseline. Without a lameness grade, a flexion result or a gait analysis recorded before starting, "is he better?" is a matter of opinion, and opinion drifts.

Cost pressure mid-course. The full course is what was studied. Half of it is not half as effective; it is untested.

Treating without a diagnosis. Joint support for an undiagnosed lameness is a way of avoiding radiographs. A subchondral bone cyst does not care what you inject.

Building a programme

1. Get a diagnosis. Lameness examination, blocks, imaging. Know which structure you are treating.
2. Record a baseline. Lameness grade, flexion responses, ideally photographs or video of the trot-up.
3. Choose the therapy for the lesion, with your veterinarian. Synovitis, cartilage degeneration and subchondral bone pathology are different problems.
4. Commit to the full protocol before you start. If the budget will not cover seven injections, do not start a seven-injection course.
5. Reassess against the baseline, not against memory.
6. Maintain between courses with oral support and, more importantly, with the training and surface management that reduce the loading in the first place.

Withdrawal times

PSGAG, hyaluronic acid and pentosan all carry detection times, commonly around seven days, and intra-articular administration extends the window. Corticosteroids given intra-articularly can be detectable for considerably longer.

Plan joint programmes around the competition calendar rather than discovering the conflict afterwards.

The most effective joint intervention on most yards is not a product at all. It is the training surface, the shoeing or foot balance, and the workload. Injectables support a structure under load. They do not remove the load.